Laura Bukavina, Urologic Oncologist at Cleveland Clinic Urology, shared an article by Cagri Akpinar et al. on X:
“Variant histology in bladder cancer poses a unique treatment challenge.
A study of 221 patients found NO survival benefit from NAC No significant differences in outcomes (OS: HR 1.88, p=0.14; CSS: HR 1.34, p=0.50; RFS: HR 1.13).
Use NAC cautiously in VH, as response may hinge on the % of urothelial component.”
The effect of neoadjuvant chemotherapy on survival outcomes inpatients with variant histologies who underwent radical cystectomy with precystectomy diagnostic accuracy: A multicenter study of the Turkish Uro-oncology Association.
Authors: Cagri Akpinar, et al.
